Carl Icahn on the sixth annual CNBC Institutional Investor Delivering Alpha Convention on September 13, 2016.
Heidi Gutman | CNBC
Bausch Health Companies Inc, previously Valeant Prescribed drugs Worldwide Inc, is a Canada-based firm that develops, manufactures and markets a spread of branded and generic prescription drugs, medical gadgets and over-the-counter merchandise. It primarily develops merchandise within the therapeutic areas of eye well being, gastroenterology and dermatology. Its dermatology merchandise deal with a spread of situations, together with actinic keratosis, zits, atopic dermatitis, psoriasis and different dermatoses. It additionally gives a number of aesthetic medical gadgets that deal with a wide range of situations, together with facial wrinkles, zits, pigmentation situations and laser hair elimination, amongst others. The gastrointestinal (GI) phase gives merchandise that deal with GI and hepatologic situations, together with hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, amongst others. Its eye well being merchandise are marketed within the following classes: Contact Lens, Pharmaceutical Merchandise and Surgical.
Inventory Market Worth: $11.Three billion ($31.93 per share)
Share Possession: 7.83%
Common Price: $25.57
Activist Commentary: Carl Icahn is the grandfather of shareholder activism and a real pioneer of the technique. Whereas he isn’t slowing down in any respect, he lately reached an settlement together with his son, Brett Icahn, to rejoin the agency because the eventual successor. Brett employed three portfolio managers to assist him search for the agency’s subsequent activist goal and that is Icahn’s first 13D submitting since Brett rejoined the agency. Brett has mentioned that he plans to make use of his father’s favored strategy of pushing firms to make adjustments designed to spice up their inventory costs, although he hasn’t dominated out pleasant bets too. This isn’t a departure from the technique Carl has succeeded with for a few years. He might be pleasant (i.e., Apple, Netflix) or he might be confrontational (i.e., Forest Labs, Biogen), typically it will depend on the response of administration. Brett is a formidable activist investor in his personal proper, not as a result of he’s Carl’s son, however as a result of he has demonstrated an extended observe document of extraordinarily profitable activist investing. A lot has been written in regards to the Sargon Portfolio he co-headed at Icahn, which at one time totaled round $7 billion and included extraordinarily worthwhile investments in firms akin to Netflix Inc. and Apple Inc. The Saragon Portfolio considerably outperformed the market with an annualized return of 27%. Nevertheless, previous to that Brett began in 2002 with Icahn as an analyst and was later liable for campaigns like Hain Celestial (280.3% return versus 46.7% for the S&P500), Take Two Interactive (81.5% versus 64.5%) and Mentor Graphics (106.4% versus 79.4%).
Icahn intends to have interaction in discussions with the corporate’s administration and board relating to methods to reinforce shareholder worth, together with the corporate’s ongoing strategic evaluate.
In Icahn’s 13D at Bausch, he states that he to intends to have interaction in discussions with the Firm relating to methods to reinforce shareholder worth, together with the corporate’s ongoing strategic evaluate and attainable board illustration. We consider he’s actually involved about strategic alternatives. First, the language about board illustration is boilerplate language for Icahn 13D filings however the language about strategic evaluate will not be. Second, the board already has two 13D shareholder administrators – Robert Hale of Worth Act and John Paulson of Paulson & Co. Extra doubtless Icahn is fascinated about creating worth by way of strategic transactions at Bausch, which was constructed on many acquisitions through the years when it operated as Valeant.
Since Icahn’s submitting, 13D shareholder Glenview Capital launched a letter to the corporate welcoming Icahn as an lively shareholder and releasing its personal plan for the corporate – dump stakes in or parts of its high-value, optimally-profiled belongings at truthful costs to lift fairness and de-lever providing possession in iconic belongings to the numerous swimming pools of capital who’re chasing a scarce variety of fairly-valued, high quality progress alternate options. As Icahn alludes to in his submitting, the corporate has already introduced that it intends to separate its eye-health enterprise into an unbiased publicly traded entity from the rest of Bausch Well being Corporations Inc. in late 2021 and Glenview helps promoting 40% of this enterprise to the general public. Administration acknowledged that it’s exploring numerous capitalization buildings and the type of the separation transaction to be able to correctly capitalize each entities post-separation. As Glenview suggests, there are additionally alternatives to create worth by promoting off different enterprise traces.
That is an space the place Icahn may definitely add worth. The attention care enterprise accounted for $3.7 billion of the corporate’s $8.6 billion of income in 2019. Icahn will definitely wish to guarantee that shareholders get full worth within the separation, which may imply a sale of the enterprise as a substitute of a separation. Who is aware of, possibly optimum worth could be derived by promoting the attention care enterprise and/or different Bausch companies to a SPAC? With the variety of SPACs being launched nowadays, it’s only a matter of time earlier than they’ve to have a look at subsidiary companies of public firms.
Ken Squire is the founder and president of 13D Monitor, an institutional analysis service on shareholder activism, and the founder and portfolio supervisor of the 13D Activist Fund, a mutual fund that invests in a portfolio of activist 13D investments.